Mesa Laboratories stock: fair value
MLABThe fair value of Mesa Laboratories under our model is $90.53, the price is 49% above.
The fair value is an estimate from our model, not a price target.
Daily figure as of 13 Nov 2026
Valuation signal
Modestly overvaluedIn our model the price counts as cheap below $64.67 and expensive above $150.89 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $150.05 (cash-flow model) and $31.02 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $77.97, at 7.8% it would be $109.38.
Where the number comes from
Half from the cash-flow model, half from earnings times the sector P/E (26.8).
Ten-year cash-flow model from smoothed free cash flow and its past growth until it reaches 3.8%. Discounted at 8.8% (floor: government bond yield 3.8% plus 5 percentage points, since beta 1.11 times the risk premium would give less); no analyst estimates were available.
Calculate with your own assumptionsThe calculation step by step
With these figures the cash flow model arrives at $150.05 per share: free cash flow for the next ten years, each year discounted to today at 8.8%, plus the terminal value for the years after. The table explains the calculation; it is not a recommendation.
Calculation as a table
| Year | Free cash flow | Source | Discount factor | Present value (discounted at 8.8%) |
|---|---|---|---|---|
| 2027 | $41.67M | extrapolated at 5.8% | 0.9189 | $38.28M |
| 2028 | $43.83M | extrapolated at 5.2% | 0.8443 | $37M |
| 2029 | $45.92M | extrapolated at 4.8% | 0.7758 | $35.63M |
| 2030 | $47.99M | extrapolated at 4.5% | 0.7129 | $34.21M |
| 2031 | $50.05M | extrapolated at 4.3% | 0.6550 | $32.78M |
| 2032 | $52.13M | extrapolated at 4.2% | 0.6019 | $31.37M |
| 2033 | $54.24M | extrapolated at 4.1% | 0.5530 | $30M |
| 2034 | $56.41M | extrapolated at 4.0% | 0.5082 | $28.66M |
| 2035 | $58.63M | extrapolated at 3.9% | 0.4669 | $27.38M |
| 2036 | $60.92M | extrapolated at 3.9% | 0.4291 | $26.14M |
| Step | Value |
|---|---|
| Sum of present values (ten years) | $321.46M |
| Terminal value: cash flow 2036 × (1 + 3.8%) / (8.8% − 3.8%) | $1.27B |
| Present value of terminal value (× 0.4291) | $542.81M |
| Equity value (sum plus present value of terminal value) | $864.27M |
| Shares (diluted) | 5.76M |
| Value per share (equity value divided by shares) | $150.05 |
| Earnings per share, last twelve months | $1.16 |
| × 26.8 (sector P/E) | $31.02 |
| Fair value (average of both parts) | $90.53 |
The model uses free cash flow after interest, which belongs to shareholders, discounted at the cost of equity. Net debt is therefore not deducted again.
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 3 Apr 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.